News Search Results
Jul 28, 2025, 08:12 ET À l'occasion de la conférence internationale de l'Alzheimer's Association (AAIC) Alamar Biosciences présente des données pionnières sur le pTau dérivé du cerveau
présentation exposera les données de la cohorte de naissance de 1946 présentant les nouvelles isoformes pTau dérivées du cerveau à l'aide du NULISAseq™ CNS Disease Panel 120 dans les échantillons présymptomatiques et post-diagnostic de la maladie d'Alzheimer, soulignant la capacité supérieure des pTau dérivés
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 08:00 ET Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference
from the wealth of data collected both at home and in the clinic in CNS-101," said Dr. Emer MacSweeney, Co-Founder & CEO of Re:Cognition Health's Brain and Mind Clinics which served as a leading CNS-101 clinical site. "The burden on study participants and patients is
More news about: Cumulus Neuroscience
Jul 28, 2025, 08:00 ET MapLight Therapeutics Announces $372.5 Million Series D Financing
substantial unmet medical need in schizophrenia, ADP and other CNS indications," said Nanna Lüneborg. "We are excited to partner with the outstanding team and investor syndicate at MapLight to fuel these important new innovations in the CNS space," said Josh Richardson,
More news about: MapLight Therapeutics, Inc.
Jul 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Jul 25, 2025, 08:00 ET Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma
sub-divided into only three categories: Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4) About VORANIGOVORANIGO is an isocitrate
More news about: Servier Pharmaceuticals
Jul 25, 2025, 07:30 ET Taiho Oncology Announces Acceptance of Abstract for Zipalertinib at the ESMO Congress 2025
CEST a.m. on Oct. 13, 2025. Title: Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Exon 20 Insertion (Ex20ins)/Other Uncommon MutationsAbstract
More news about: Taiho Oncology
Jul 24, 2025, 07:00 ET Corero Network Security Leads in 2025 SPARK Matrix With Higher Customer Impact
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the DDoS protection specialists, today announced it has been named both a Leader and an Emerging Innovator in the 2025 SPARK Matrix
More news about: Corero Network Security
Jul 23, 2025, 11:14 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Jul 23, 2025, 08:00 ET Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder
and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent
More news about: Indivior PLC
Jul 22, 2025, 11:19 ET Natus announces Moberg CNS integration with NeuroWorks for advanced EEG
NeuroWorks, the Moberg CNS Monitor enhances EEG visibility, offering real-time EEG, annotations, and video in one platform to support comprehensive, data-driven patient care. Already trusted for continuous EEG monitoring in critically ill ICU patients, this integration with the Moberg CNS expands the presence
More news about: Natus Medical Incorporated
Jul 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Jul 22, 2025, 08:19 ET Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins
marks the first pharmacologic test of GDNF in human liver-engrafted mice — setting the stage for potential first-in-class metabolic applications beyond CNS indications. "This landmark agreement allows a real-world, controlled comparison of GDNF's metabolic effects alongside semaglutide — the current
More news about: Hoth Therapeutics, Inc.
Jul 21, 2025, 20:00 ET Neuraxpharm continues international expansion with launch of Neuraxpharm Australia
Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil® (modafinil), and
More news about: Neuraxpharm
Jul 21, 2025, 06:30 ET Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Jul 18, 2025, 06:32 ET Weekly Recap: 14 Health Press Releases You Need to See
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform The proceeds will be used to accelerate the development of GAIA-based Alzheimer's
More news about: PR Newswire
Jul 17, 2025, 16:13 ET COHEN & STEERS REPORTS RESULTS FOR SECOND QUARTER 2025
YORK, July 17, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the quarter ended June 30, 2025. The earnings release along with the accompanying earnings
More news about: Cohen & Steers, Inc.
Jul 17, 2025, 11:00 ET BrainXell, Inc. Strengthens Executive Leadership with Paul Marcus and Dr. Su-Chun Zhang
Su-Chun Zhang, an internationally recognized expert in stem cell neuroscience whose groundbreaking work in human iPSC differentiation and CNS development underpins BrainXell's core technology platform. He now serves as Advising Chief Scientific Officer. "We are incredibly fortunate
More news about: BrainXell, Inc.
Jul 16, 2025, 13:25 ET G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise
types include functional and binding assays, while product types range from cell lines to detection kits. Applications span cancer, cardiovascular, CNS, and respiratory diseases. The report also covers regional markets across North America, Europe,
More news about: BCC Research LLC
Jul 14, 2025, 07:00 ET Corero Network Security Partners with IP Networks to Expand Reach of Adaptive DDoS Protection Across North America
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced a strategic partnership with
More news about: Corero Network Security
Jul 14, 2025, 03:38 ET Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
Illimis Therapeutics is a pioneering biotechnology company at the forefront of developing innovative therapies for challenging central nervous system (CNS) and immune-related diseases. The company's core strength lies in its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This cutting-edge
More news about: Illimis Therapeutics
Jul 10, 2025, 17:46 ET Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight
Lewy Body Dementia Market Report Neflamapimod, an investigational central nervous system (CNS) therapy developed by CervoMed and originally licensed from Vertex Pharmaceuticals, has been granted Fast Track designation (FTD) by the FDA for the
More news about: DelveInsight Business Research, LLP
Jul 10, 2025, 11:00 ET BrainXell, Inc. Appoints Katherine Vega Stultz as Chief Executive Officer and Board Director
July 10, 2025 /PRNewswire/ -- BrainXell, Inc., a leading biotechnology company developing iPSC-based CNS disease models and regenerative cell therapies, announces the appointment of Katherine Vega Stultz as its new Chief Executive
More news about: BrainXell, Inc.
Jul 10, 2025, 09:20 ET Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
and CEO of Nuvation Bio. "These updates address critical needs for patients across their treatment journeys, especially with the prevalence of CNS involvement for those living with ROS1+ NSCLC. Additionally, this version builds further upon a previous guideline update that importantly highlights
More news about: USA News Group
Jul 10, 2025, 08:30 ET BRENIG THERAPEUTICS ANNOUNCES APPOINTMENTS OF DAVID L. LUCCHINO AS CEO AND TIEN DAM, M.D., AS CHIEF MEDICAL OFFICER, EXPANDS PIPELINE
small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2)—a key protein implicated in the pathogenesis of Parkinson's disease. Designed to maximize CNS exposure while minimizing peripheral activity, BT-267 offers a differentiated profile aimed at reducing off-target and systemic side effects. BT-267
More news about: Brenig Therapeutics Inc.
Jul 10, 2025, 08:00 ET Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND-201 (methylone) for the Treatment of PTSD
5HT-2a (i.e., not hallucinogenic). Transcend is developing TSND-201 as a rapid-acting and durable treatment for PTSD and other central nervous system (CNS) indications. TSND-201 is an investigational medication. About PTSDPTSD is a mental health condition that can occur after experiencing
More news about: Transcend Therapeutics